Gustavo Viani: Prostate SBRT with an integrated focal boost demonstrated excellent 5-year outcomes

Gustavo Viani shared a post on LinkedIn:

“Prostate SBRT with an integrated focal boost demonstrated excellent 5-year outcomes

-Study Overview:
The hypo-FLAME trial explored a novel approach for treating intermediate- and high-risk prostate cancer using ultra-hypofractionated SBRT combined with a focal boost to the tumor.

-Treatment Details:
•  received 35 Gy in 5 weekly sessions to the whole prostate
• An additional integrated focal boost of up to 50 Gy targeted the tumor based on MRI imaging
• Dose constraints for surrounding healthy tissues were prioritized to  side effects

– Results:
• 5-Year Biochemical Disease-Free Survival (bDFS): 93% (CI 86%-97%)
• Toxicity Rates at 5 Years:
• Grade 2+ GU toxicity: 12%
• Grade 2+ GI toxicity: 4%.”

Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial

Authors: Cédric Draulans, Karin Haustermans, Floris J. Pos, Uulke A. van der Heide, Lisa De Cock, Jochem van der Voort van Zyp, Hans De Boer, Robert J. Smeenk, Martina Kunze-Busch, Evelyn M. Monninkhof, Robin De Roover, Sofie Isebaert and Linda G.W. Kerkmeijer.

Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.